MISSION
Using state of the art technologies, we aim at manufacturing kits for the analysis and editing of therapeutically relevant antibodies such as monoclonal antibodies effective against immunology disorders or oncology.
Our kits for antibody genome sequencing and editing are based on the NGS method (next generation sequencing) and the CRISPR-Cas9 method (clustered regularly interspaced short palindromic repeats-associated protein 9).